PPT-EGFR-Mutated Advanced NSCLC

The Coming Paradigm Shift Faculty Suresh S Ramalingam MD Professor of HematologyOncology Director Lung Cancer Program Winship Cancer Institute Emory University Atlanta Georgia Program Goals. Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. Increases . Safety Window in Preclinical Studies. Bryan A. Irving Ph.D. . Vice President, Cancer Immunology @CytomX Therapeutics, Inc.. Presenter Disclosure Information. The following relationships exist related to this presentation:. MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson Cancer Center. University of Pennsylvania Health System. Disclosures of Conflicts of Interest. Ms. Eaby-Sandy, MSN, CRNP, OCN. ®. Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . The Role of Antiangiogenic Agents in the Changing Treatment Paradigm of NSCLC: Expert Perspectives Moderator Solange Peters, MD, PhD Chair, Medical Oncology Department of Oncology Centre Hospitalier Universitaire Vaudois (CHUV) actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Disclosures for . Dr. Langer. Advisory Committee. Abbott Laboratories, AstraZeneca Pharmaceuticals LP, . Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson . Cancer Center of the University of Pennsylvania. Disclosure of Conflicts of Interest. Beth . Eaby. -Sandy, MSN, CRNP, . O. CN. ®. Consequences of the Lack of Patients of color & Structural barriers to Quality. Christopher S. Lathan, M.D., M.S., M.P.H. Assistant Professor of Medicine. Faculty Director of Cancer Care Equity, Dana-Farber Cancer Institute. Prediction. . and. . Data Sorting. Zhengtao. Li/06-24-2019. Introduction. https://www.ppdi.com/About/About-Drug-Discovery-and-Development. What . medchem. should focus?. IP. Target engagement. ADME property. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. Ana Rima. Lung Cancer: Incidence and Mortality. New cases in 2013: 228,190. 40% with stage IV disease at presentation (~ 90,000). ~ 160,000 deaths in 2012, comparable to prostate, pancreas, breast, and colon cancer combined. Ana Rima. PENDAHULUAN. 2. Kanker Paru. P. enyebab . utama kematian akibat kanker . . Terdiagnosis pada stadium lanjut. Pembagian pasien kanker paru berdasarkan stadium di bangsal paru RSDM. Th. 2014 . Professor Rachel Butler. The genomic complexity of advanced NSCLC. Jordan et al. Cancer Discovery (2017). >50% NSCLC now have actionable variant. Treatment algorithm. NHSE: National Genomic Test Directory.